top of page

Accelerating Therapies

We aim to fast-track science, fund innovative research, and push progress forward to uncover the next generation therapies. With this integrated approach, our goal is to stop PF in its tracks.


What We Do

Three Lakes Consortium for PF (TLC4PF)

The Three Lakes Consortium for PF (TLC4PF) aims to accelerate therapies for the treatment of PF.

B4PF: Understanding Early Disease

To develop therapies that prevent the development of PF, it is essential to study the earliest aspects of disease pathogenesis.

A Global Collaboration for PF

Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is a clinically focused research program funded by the Australian National Health and Medical Research Council.


Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) is a comprehensive, multicenter, and multi-investigator study.

Enlil Therapeutics

Three Lakes Foundation has provided funding to support Enlil Therapeutics in its quest to identify compounds that activate telomerase.

Current Programs

Breath Biopsy for Early PF Detection

Metabolic changes associated with IPF and interstitial lung abnormality (ILA) may lead to the production of unique, volatile, organic compounds (VOCs) detectable in breath.

The Impact of Antimicrobial Therapy in IPF

Clean-UP IPF was the first pragmatic trial in IPF that looks at whether antimicrobial therapy would improve hospitalization or decrease death.

Targeted Therapies for PF

Selectively targeting the cells that drive PF would protect the patients from systemic side effects associated with therapies.


EGCG was discovered as an antifibrotic in pre-clinical in vivo studies and its mechanism of action blocking collagen accumulation published in 2017.

An Atlas of IPF Lung Cells

This research study was designed to identify the cellular changes that occur in the human lung cells as fibrosis develops.

Past Programs

bottom of page